Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Barclays Sticks to Its Buy Rating for Boston Scientific (BSX)

Tipranks - Tipranks - Tue Mar 31, 2:09AM CDT

Barclays analyst Matt Miksic reiterated a Buy rating on Boston Scientific today and set a price target of $124.00.

End of Quarter Sale - 50% Off TipRanks

Miksic covers the Healthcare sector, focusing on stocks such as Medtronic, Cooper Co, and Boston Scientific. According to TipRanks, Miksic has an average return of 2.7% and a 51.48% success rate on recommended stocks.

In addition to Barclays, Boston Scientific also received a Buy from TD Cowen’s Josh Jennings in a report issued yesterday. However, on March 17, TipRanks – OpenAI downgraded Boston Scientific (NYSE: BSX) to a Hold.

See Insiders’ Hot Stocks on TipRanks >>

Based on Boston Scientific’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $5.29 billion and a net profit of $668 million. In comparison, last year the company earned a revenue of $4.56 billion and had a net profit of $566 million

Read More on BSX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).